Finerenone (Kerendia, BAY94-8862)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Left Ventricular Systolic Dysfunction
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Trial Timeline
Jun 1, 2026 → Dec 30, 2030
NCT ID
NCT07192952About Finerenone (Kerendia, BAY94-8862)
Finerenone (Kerendia, BAY94-8862) is a phase 3 stage product being developed by Bayer for Left Ventricular Systolic Dysfunction. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07192952. Target conditions include Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07192952 | Phase 3 | Recruiting |
| NCT05705271 | Approved | Completed |
| NCT05457283 | Phase 3 | Recruiting |
Competing Products
11 competing products in Left Ventricular Systolic Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD1305 + Placebo | AstraZeneca | Phase 2 | 52 |
| Valsartan + Amlodipine + Hydrochlorothiazide + Losartan | Novartis | Phase 3 | 77 |
| Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B | Bayer | Phase 1 | 30 |
| BAY2701250 IV + Placebo IV + BAY2701250 SC + Placebo SC | Bayer | Phase 1 | 30 |
| Finerenone (Kerendia, BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Inhaled Iloprost + Placebo | Bayer | Phase 2 | 49 |
| Levosimendan | Orion Corporation | Pre-clinical | 20 |
| MK0954, /Duration of Treatment : 5 Years + Comparator : atenolol /Duration of Treatment : 5 Years | Organon | Phase 3 | 72 |
| Allo-hMSCs + Placebo | Longeveron | Phase 1 | 25 |
| Lomecel-B medicinal signaling cells | Longeveron | Phase 2 | 44 |